Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novavax's Total Liabilities for the quarter that ended in Mar. 2026 was €1,027.6 Mil.
Novavax's quarterly Total Liabilities
declined
from Sep. 2025 (€1,138.75 Mil) to Dec. 2025 (€1,113.84 Mil) and
declined
from Dec. 2025 (€1,113.84 Mil) to Mar. 2026 (€1,027.55 Mil).
Novavax's annual Total Liabilities
declined
from Dec. 2023 (€2,305.72 Mil) to Dec. 2024 (€2,085.97 Mil) and
declined
from Dec. 2024 (€2,085.97 Mil) to Dec. 2025 (€1,113.84 Mil).
The historical data trend for Novavax's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Novavax's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of €1,027.6 Mil mean?
Novavax (WBO:NVAX) has a Total Liabilities of €1,027.6 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Novavax and its competitors.
Is Novavax's Total Liabilities too high?
Novavax's current Total Liabilities is €1,027.6 Mil. Overall, Novavax has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Total Liabilities compare to JBIO and AVLN?
Novavax's Total Liabilities of €1,027.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Novavax and its competitors. Novavax's current Total Liabilities is €1,027.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (WBO:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.25, compared to a current price of €6.37 — trading 96% above its estimated fair value. The current Total Liabilities is €1,027.6 Mil. Novavax's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Novavax (WBO:NVAX), the current Total Liabilities is €1,027.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (WBO:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of €6.37 is trading 96% above its estimated GF Value™ of €3.25.
GuruFocus considers Novavax to be Significantly Overvalued.
Key valuation signals for WBO:NVAX:
Total Liabilities: €1,027.6 Mil
GF Value™: €3.25 vs. price of €6.37 (96% above fair value)
No single metric tells the full story. See the WBO:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
29GF Score
Get the complete analysis for WBO:NVAX
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NVAX has been successfully added to your 
